Yuhan Corporation

Eui Chul Lee

Hyun Ho Choi

So Young Kim

Sol Park

Tae Dong Han

Eun Kyung Kim

Na Ry Ha

Hee Jae Tak

Cheol Hee Lim

Hyok Jun Cho

Da Na Jeong

Na Yeon Yang

Dong Hoon Kim

Su Bin Choi

Mi Kyeong Ju

Tae Wang Kim

The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

Growing community of inventors

Yongin-si, South Korea

Eui Chul Lee